In a pilot study, we wanted to influence the food selection of employees in a pediatric clinic bistro aiming to increase the sale of "healthy" grain buns (number and proportion of all sold buns). During basic assessment, the mean weekly sale of grain buns was 98 (52.3%) and in the second week of highlighting them on a green napkin under a transparent hood (intervention 1) reached 124 (54.6%). However, just when starting intervention 2 (position in front of the display), the bistro was closed due to the Coronavirus pandemic. Thus, necessary public health measures stopped our interventional public health experiment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449524 | PMC |
| http://dx.doi.org/10.1038/s41430-020-00728-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of the Preservation of Residual Kidney Function on Hemodialysis Survival: Results from the BISTRO Trial.
Kidney360
October 2024
School of Medicine, Keele University, Keele, Staffordshire.
Background: Preservation of residual kidney function (RKF) in dialysis patients has been associated with improved survival. RKF in the BISTRO trial was relatively well preserved and here we describe its association with survival during the trial and extended follow-up.
Methods: RKF, measured as the average urea and creatinine clearance (GFR) or 24-hour urine volume was assessed at baseline, one, two and three months and three-monthly up to 2 years in incident haemodialysis patients.
Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT.
Health Technol Assess
September 2024
Centre for Health Economics at Warwick, University of Warwick, Coventry, UK.
Article Synopsis
- The study evaluated the economic benefits of using bioimpedance spectroscopy for fluid management in dialysis patients compared to standard methods, focusing on its impact on kidney function and risk of anuria.
- Conducted in 34 UK dialysis centers, the trial involved 439 adult patients with some residual kidney function, testing how bioimpedance data could optimize patient care.
- The primary goal was to assess the cost-effectiveness of this approach by calculating the cost per additional quality-adjusted life-year gained over 24 months.
Structure and function of therapeutic antibodies approved by the US FDA in 2023.
Antib Ther
April 2024
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Roselló Street 132, 08036, Barcelona, Spain.
Article Synopsis
- In 2023, the FDA approved 55 new molecular entities, including 12 therapeutic antibodies, and 5 non-antibody protein drugs, making protein drugs 31% of total approvals.
- Of the 12 approved antibodies, 8 were standard IgG, 3 were bivalent bispecific, and 1 was a trivalent bispecific antibody, with no new antibody-drug conjugates or CAR-T therapies approved.
- Key targets for the approved antibodies included various receptors for conditions like cancer, Alzheimer's disease, and severe colitis, addressing specific orphan indications and other serious health issues.
Monitoring residual kidney function in haemodialysis patients using timed urine collections: validation of the use of estimated blood results to calculate GFR.
Physiol Meas
August 2022
School of Medicine, Faculty of Medicine and Health Sciences, Keele University, United Kingdom.
Article Synopsis
- There is an increasing focus on measuring residual kidney function (RKF) in hemodialysis patients, leading to a need for more practical methods of assessing plasma levels of urea and creatinine.
- Interdialytic urine collections, while useful for research, are often impractical in everyday care due to the need for blood samples before and after.
- A study found that using estimated plasma levels based on the steady state assumption resulted in minimal differences in calculations of glomerular filtration rate (GFR), suggesting that patients could efficiently collect urine for 24 hours prior to regular blood tests to monitor RKF.
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
BioDrugs
May 2022
Biomedscapes, Bridgewater, NJ, 08807, USA.
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab and casirivimab, Vir's sotrovimab, Celltrion's regdanvimab, and Lilly's bebtelovimab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!